HRP20150225T1 - Derivati acilbenzena - Google Patents
Derivati acilbenzena Download PDFInfo
- Publication number
- HRP20150225T1 HRP20150225T1 HRP20150225TT HRP20150225T HRP20150225T1 HR P20150225 T1 HRP20150225 T1 HR P20150225T1 HR P20150225T T HRP20150225T T HR P20150225TT HR P20150225 T HRP20150225 T HR P20150225T HR P20150225 T1 HRP20150225 T1 HR P20150225T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- fluoro
- hydroxy
- oxadiazol
- benzamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 hydroxyethyl group Chemical group 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Spoj predstavljen općom formulom (I):
[Kemijska formula 1]
[image]
naznačen time, što
R1 predstavlja neka hidroksi C1-C6 alkil grupa ili neka hidroksi C3-C6 cikloalkil grupa, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta koji se biraju iz grupe supstituenata α, a subgrupu supstituenata α čine hidroksilna grupa i karbamoil grupa,
R2 predstavlja metil grupa ili etil grupa,
R3 predstavlja neka C1-C6 alkil grupa ili neka C3-C6 cikloalkil grupa, od kojih svaka može biti supstituirana sa 1 to 3 atoma halogena, i
R4 predstavlja neki atom halogena;
ili neka njegova farmaceutski prihvatljiva sol.
2. Spoj prema Zahtjevu 1, naznačen time, što R1 predstavlja neka hidroksi C1-C3 alkil grupa ili neka hidroksi C3-C4 cikloalkil grupa, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta koji se biraju iz grupe supstituenata α.
3. Spoj prema Zahtjevu 1, naznačen time, što R1 predstavlja hidroksietil grupa, hidroksipropil grupa, hidroksiizopropil grupa ili hidroksiciklopentil grupa, od kojih svaka može biti supstituirana sa jednim substituentom koji se bira iz grupe supstituenata α.
4. Spoj prema bilo kojem od Zahtjeva 1 do 3, naznačen time, što R3 predstavlja neka C1-C4 alkil grupa ili neka C3-C4 cikloalkil grupa, od kojih svaka može biti supstituirana sa 1 do 3 atoma halogena.
5. Spoj prema bilo kojem od Zahtjeva 1 do 3, naznačen time, što R3 predstavlja izopropil grupa, terc-butil grupa, ciklopropil grupa ili ciklobutil grupa, od kojih svaka može biti supstituirana sa jednim atomom halogena.
6. Spoj prema bilo kojem od Zahtjeva 1 do 5, naznačen time, što R4 predstavlja atom fluora.
7. Spoj prema Zahtjevu 1, koje se bira iz grupe koju čine slijedeći spojevi:
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-N-[(2S)-2,3-dihidroksipropil]-2-fluoro benzamid;
N-[(1S)-2-аmino-1-(hidroksimetil)-2-oksoеtil]-4-(5-{(1R)-1-[4-(ciklopropilkarbonil)-fenoksi]propil}-1,2,4-oksadazol-3-il)-2-fluorobenzamid;
4-((5-{(1R]-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[(1R)-2-hidroksi-1-metiletil]benzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N- [(1S)-2-hidroksi-1-metiletil]benzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[(2R)-2,3-dihidroksipropil]-2-fluorobenzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N- [2-hidroksi-1-(hidroksimetil)etil]benzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[(1S)-2-hidroksi-1-metiletil]benzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]etil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[(1R,2R)-2-hidroksiciklopentil]benzamid;
4-((5-{(1R)-1-[9-(ciklopropilkarbonil)fenoksi]etil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-(1R)-2- hidroksi-1-metiletil]benzamid;
4-((5-{(1R)-1-[4-(ciklopropilkarbonil)fenoksi]etil}-1,2,4-oxadiazol-3-il)-2-fluоro-N-[(1S,2S)-2-hidroksiciklopentil]benzamid;
4-((5-[(1R]-1-[4-(2,2-dimetilpropanoil)fenoksi]propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[2-hidroksi-1-(hidroksimetil)etil]benzamid;
4-((5-{(1R)-1-[4-(ciklobutilkarbonil)fenoksi)propil}-1,2,4-oksadiazol-3-il)-2-fluoro-N-[2-hidroksi-1-(hidroksimetil)etil]benzamid;
2-fluoro-4-{5-[(1R)-1-(4-[(1-fluorociklopropil)karbonil]fenoksi}propil]-1,2,4-oksadiаzol-3- il]-N-[2-hidroksi-1-(hidroksimetil)etil]benzamid;
2-fluoro-N-[(1R)-2-hidroksi-1-metiletil]-4-{5-[(1R)-1-(4-izobutirilfenoksi)propil]-1,2,4- oksadiazol-3-il]benzamid; i
2-fluoro-N-[2-hidroksi-1-(hidroksimetil)etil]-4-{5-[(1R)-1-(izobutirilfenoksi)propil]-1,2,9-oksadiazol-3-il]benzamid.
8. Farmaceutska kompozicija, naznačena time, što sadrži kao aktivni sastojak spoj prema bilo kojem od Zahtjeva 1 do 7, ili neku njegovu farmaceutski prihvatljivu sol.
9. Uporaba farmaceutske kompozicije prema Zahtjevu 8 za tretiranje tipa 1 dijabetesa, tipa 2 dijabetesa ili debljine.
10. Uporaba farmaceutske kompozicije prema Zahtjevu 8 za zaštitu β-stanica ili pankreasa.
11. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 7, ili neke njegove farmaceutski prihvatljive soli, za dobijanje farmaceutske kompozicije.
12. Uporaba prema Zahtjevu 11, gdje je ta farmaceutska kompozicija za tretiranje tipa 1 dijabetesa, tipa 2 dijabetesa ili debljine.
13. Uporaba prema Zahtjevu 11, gdje je ta farmaceutska kompozicija za zaštitu stanica ili pankreasa.
14. Uporaba nekog spoja prema bilo kojem od Zahtjeva 1 do 7 u tretmanu tipa 1 dijabetesa, tipa 2 dijabetesa ili debljine.
15. Uporaba nekog spoja prema bilo kojem od Zahtjeva 1 do 7 za zaštitu β-stanica ili pankreasa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010231471 | 2010-10-14 | ||
| JP2011022325 | 2011-02-04 | ||
| EP11832583.6A EP2628733B1 (en) | 2010-10-14 | 2011-10-13 | Acylbenzene derivative |
| PCT/JP2011/073489 WO2012050151A1 (ja) | 2010-10-14 | 2011-10-13 | アシルベンゼン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150225T1 true HRP20150225T1 (hr) | 2015-06-19 |
Family
ID=45938375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150225TT HRP20150225T1 (hr) | 2010-10-14 | 2015-02-26 | Derivati acilbenzena |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8722711B2 (hr) |
| EP (1) | EP2628733B1 (hr) |
| JP (2) | JP5069813B2 (hr) |
| KR (1) | KR101829086B1 (hr) |
| CN (1) | CN103249726B (hr) |
| AU (1) | AU2011314712B2 (hr) |
| BR (1) | BR112013009043B8 (hr) |
| CA (1) | CA2814628C (hr) |
| CO (1) | CO6771403A2 (hr) |
| CY (1) | CY1116303T1 (hr) |
| DK (1) | DK2628733T3 (hr) |
| ES (1) | ES2532706T3 (hr) |
| HK (1) | HK1185082A1 (hr) |
| HR (1) | HRP20150225T1 (hr) |
| IL (1) | IL225724A (hr) |
| MX (1) | MX2013004176A (hr) |
| MY (1) | MY160300A (hr) |
| NZ (1) | NZ610145A (hr) |
| PL (1) | PL2628733T3 (hr) |
| PT (1) | PT2628733E (hr) |
| RS (1) | RS53965B1 (hr) |
| RU (1) | RU2585765C2 (hr) |
| SG (1) | SG189320A1 (hr) |
| SI (1) | SI2628733T1 (hr) |
| SM (1) | SMT201500067B (hr) |
| TW (1) | TWI487699B (hr) |
| WO (1) | WO2012050151A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014001767A2 (pt) | 2011-07-29 | 2017-02-14 | Daiichi Sankyo Co Ltd | composto, composição farmaccêutica, uso de um composto, e, método para o tratamento de uma doença |
| WO2013108800A1 (ja) | 2012-01-18 | 2013-07-25 | 第一三共株式会社 | 置換フェニルアゾール誘導体 |
| JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
| WO2017104782A1 (ja) * | 2015-12-17 | 2017-06-22 | 第一三共株式会社 | オキサジアゾール化合物の製造方法 |
| TW201731506A (zh) * | 2016-01-19 | 2017-09-16 | 第一三共股份有限公司 | 糖尿病治療劑之倂用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4401108A1 (de) * | 1994-01-17 | 1995-07-20 | Bayer Ag | 1,2,4-Oxadiazol-Derivate |
| AU9575698A (en) * | 1997-10-06 | 1999-04-27 | Eli Lilly And Company | Novel compounds useful as neuro-protective agents |
| CA2418134A1 (en) | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| KR101154830B1 (ko) | 2003-12-24 | 2012-06-18 | 프로시디온 리미티드 | Ｇｐｃｒ 수용체 효능제로서의 헤테로사이클릭 유도체 |
| WO2007003960A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| GB0513257D0 (en) * | 2005-06-30 | 2005-08-03 | Prosidion Ltd | Compounds |
| WO2007003962A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
| WO2007116229A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
| EP2241558A1 (en) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| RU2536409C2 (ru) * | 2009-08-05 | 2014-12-20 | Дайити Санкио Компани, Лимитед | Амидное производное |
| JP5546543B2 (ja) | 2009-08-05 | 2014-07-09 | 第一三共株式会社 | スルホン誘導体 |
| GB201006166D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
-
2011
- 2011-10-13 BR BR112013009043A patent/BR112013009043B8/pt not_active IP Right Cessation
- 2011-10-13 PL PL11832583T patent/PL2628733T3/pl unknown
- 2011-10-13 MX MX2013004176A patent/MX2013004176A/es active IP Right Grant
- 2011-10-13 WO PCT/JP2011/073489 patent/WO2012050151A1/ja active Application Filing
- 2011-10-13 AU AU2011314712A patent/AU2011314712B2/en not_active Ceased
- 2011-10-13 EP EP11832583.6A patent/EP2628733B1/en active Active
- 2011-10-13 RU RU2013121816/04A patent/RU2585765C2/ru not_active IP Right Cessation
- 2011-10-13 PT PT11832583T patent/PT2628733E/pt unknown
- 2011-10-13 ES ES11832583.6T patent/ES2532706T3/es active Active
- 2011-10-13 CN CN201180059656.5A patent/CN103249726B/zh not_active Expired - Fee Related
- 2011-10-13 JP JP2012527924A patent/JP5069813B2/ja active Active
- 2011-10-13 MY MYPI2013001311A patent/MY160300A/en unknown
- 2011-10-13 US US13/879,076 patent/US8722711B2/en active Active
- 2011-10-13 TW TW100137080A patent/TWI487699B/zh not_active IP Right Cessation
- 2011-10-13 RS RS20150151A patent/RS53965B1/en unknown
- 2011-10-13 KR KR1020137009191A patent/KR101829086B1/ko active IP Right Grant
- 2011-10-13 SG SG2013026281A patent/SG189320A1/en unknown
- 2011-10-13 NZ NZ610145A patent/NZ610145A/en not_active IP Right Cessation
- 2011-10-13 CA CA2814628A patent/CA2814628C/en not_active Expired - Fee Related
- 2011-10-13 SI SI201130404T patent/SI2628733T1/sl unknown
- 2011-10-13 DK DK11832583T patent/DK2628733T3/en active
-
2012
- 2012-08-17 JP JP2012180891A patent/JP5869985B2/ja active Active
-
2013
- 2013-04-11 IL IL225724A patent/IL225724A/en active IP Right Grant
- 2013-05-10 CO CO13117693A patent/CO6771403A2/es not_active Application Discontinuation
- 2013-11-11 HK HK13112624.4A patent/HK1185082A1/xx not_active IP Right Cessation
-
2015
- 2015-02-20 CY CY20151100181T patent/CY1116303T1/el unknown
- 2015-02-26 HR HRP20150225TT patent/HRP20150225T1/hr unknown
- 2015-03-18 SM SM201500067T patent/SMT201500067B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150225T1 (hr) | Derivati acilbenzena | |
| RU2500673C2 (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| JP2014505037A5 (hr) | ||
| JP2009528273A5 (hr) | ||
| HRP20170363T1 (hr) | Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret) | |
| JP2010540462A5 (hr) | ||
| PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| JP2015520769A5 (hr) | ||
| CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| ZA200403137B (en) | Dibenzylamine compound and medicinal use thereof | |
| RU2016110755A (ru) | Соединение, ингибирующее активности киназ ВТК и/или JAK3 | |
| RU2009144113A (ru) | Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1 | |
| RU2011102560A (ru) | Соединение карбоновой кислоты | |
| CA2522435A1 (en) | Inhibitors of akt activity | |
| JP2007523905A5 (hr) | ||
| JP2007519754A5 (hr) | ||
| JP2017530199A5 (hr) | ||
| JP2007514003A5 (hr) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2017500321A5 (hr) | ||
| HRP20140105T1 (hr) | Novi inhibitori seh i njihova upotreba | |
| JP2014523400A5 (hr) | ||
| JP2011510029A5 (hr) |